NEW DELHI: In what could be good news for patients, Indian Patent Office (IPO) has rejected MNC AbbVie’s patent application for its blockbuster cancer drug Venetoclax citing lack of inventive step.

Indian pharmaceutical companies head into 2026 with a clearer tilt towards specialty medicines as sustained pricing pressure continues to weigh on returns from traditional generics. With export ...

Jithin (name changed) was an autorickshaw driver in Kerala, ferrying schoolchildren through the crowded lanes every morning and evening. His modest earnings barely covered food and his children’s ...

TORONTO — Novo Nordisk Canada is considering competing with generic versions of its brand-name Ozempic and Wegovy drugs by introducing renamed, lower-priced copies of the medications. Health Canada ...

Ten years after the first biosimilar launched on the U.S. market, the FDA is taking steps to make biosimilar development and pharmacy substitution more like that of generics, reducing the cost of the ...

FRANKFURT (Reuters) -Novartis' blockbuster heart treatment Entresto saw sales growth stall in the third quarter of the year, dragging the Swiss company's shares lower, as its top-selling drug comes ...

Jamie Dimon is right to be alarmed about our national-security vulnerabilities, especially an overreliance on China and India for generic prescription drugs (“Investments for National Security,” op-ed ...

President Trump has delayed imposing tariffs on pharmaceuticals to allow for more negotiations with drug companies. (Francis Chung/Bloomberg News) The Trump administration says it doesn't plan to ...

The federal government will not impose tariffs on generic pharmaceuticals manufactured overseas, and instead focus on brand-name drugs, according to an Oct. 8 report from The Wall Street Journal. In a ...